Prilenia Plans To Continue With Pridopidine In ALS Despite Platform Study Miss

Pridopidine is the latest ALS drug candidate to miss the primary endpoint in the HEALEY-ALS platform study, but the S1R agonist did indicate potential benefits in speech and a key biomarker of the disease.

Neurodegeneration
Prilenia still hopes to advance pridopidine in ALS • Source: Shutterstock

Prilenia and the center conducting a platform trial of potential amyotrophic lateral sclerosis (ALS) therapies revealed that the company’s drug candidate pridopidine failed to meet statistical significance for the primary and secondary endpoints of the study. However, Prilenia said it plans to continue developing the selective sigma 1 receptor (S1R) agonist in ALS, while the investigator-initiated study’s sponsor said the drug showed potential for benefit in speech and other aspects of the neurodegenerative disease.

The Healey and AMG Center for ALS at Massachusetts General Hospital is conducting the HEALEY-ALS Phase II/III platform study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

More from R&D

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.